Investors

Press Releases

Feb 26, 2024 7:45am EST

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Jan 16, 2024 8:15am EST

iBio Announces Participation in 23rd Annual PepTalk Conference

Dec 26, 2023 7:15am EST

iBio Amends and Extends Maturity of Credit Agreement

Dec 05, 2023 8:00am EST

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 27, 2023 5:20pm EST

iBio Announces Reverse Stock Split

Nov 01, 2023 8:24am EDT

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 10, 2023 8:00am EDT

iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics

Oct 02, 2023 6:45am EDT

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023 4:19pm EDT

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 21, 2023 4:05pm EDT

iBio Announces Amendment to Credit Agreement with Woodforest

Previous
1
2
3
4
5
6
7
8
9
10
…19
Next